PPARs in Alzheimer's Disease
Author Information
Author(s): Markus P. Kummer, Michael T. Heneka
Primary Institution: Department of Neurology, University of Bonn
Hypothesis
PPARs might be beneficial for CNS disorders possessing an inflammatory component.
Conclusion
PPAR agonists may have therapeutic potential for Alzheimer's disease by modulating inflammation and amyloid processing.
Supporting Evidence
- NSAID treatment reduces AD risk by as much as 80%.
- PPARγ activation in microglial cells suppressed inflammatory cytokine expression.
- PPARγ agonists have been shown to reduce amyloid plaque burden in animal models.
- Clinical trials indicate that rosiglitazone improves cognition in some AD patients.
- PPARγ activation enhances Aβ clearance from the brain.
Takeaway
This study looks at how certain proteins in our body can help fight Alzheimer's disease by reducing inflammation and helping clear harmful substances from the brain.
Methodology
The study reviews existing literature and clinical trials on the effects of PPAR agonists in Alzheimer's disease models.
Potential Biases
Potential bias in the interpretation of results due to the reliance on existing studies and models.
Limitations
The effects of PPARγ agonists may vary based on individual genetic factors, such as the presence of the ApoE4 allele.
Participant Demographics
The study references trials involving patients with mild to moderate Alzheimer's disease, including those with and without the ApoE4 allele.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website